BASEL, Switzerland — September 30, 2026
Roche announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for fenebrutinib under Priority Review for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The filing is supported by results from three Phase III studies, including FENhance 1 and FENhance 2 in RMS and FENtrepid in PPMS. In the RMS studies, fenebrutinib reduced annualized relapse rates by 51.1% and 58.5% versus teriflunomide, respectively, over 96 weeks. In FENtrepid, fenebrutinib met the primary non-inferiority endpoint versus ocrelizumab for disability progression, with a numerical 12% reduction in progression risk.
Fenebrutinib Shows Relapse Reduction in RMS
FENhance 1 and FENhance 2 demonstrated statistically significant reductions in annualized relapse rates with fenebrutinib compared with teriflunomide. The reductions were 51.1% in FENhance 1 (p<0.001) and 58.5% in FENhance 2 (p<0.00001) over 96 weeks, while measures of 12-week composite confirmed disability progression showed consistent positive trends favoring fenebrutinib. The trials also evaluated active and chronic brain lesions as measures of disease activity. Roche said the findings support further evaluation of fenebrutinib as an oral treatment for RMS, although the FDA will independently assess the complete clinical and safety dataset as part of the NDA review.
FENtrepid Evaluates Disability Progression in PPMS
The Phase III FENtrepid study met its primary endpoint of non-inferiority to ocrelizumab for reducing disability progression in PPMS. Fenebrutinib produced a numerical 12% reduction in the risk of 12-week composite confirmed disability progression, with a hazard ratio of 0.88 (95% CI: 0.75–1.03), compared with ocrelizumab. Roche reported that treatment effects were observed across patient subgroups, including participants without active inflammation, with treatment curves separating as early as 24 weeks. FENtrepid is notable because PPMS has historically presented substantial challenges in slowing disability progression, but the reported numerical difference does not establish superiority over ocrelizumab because the study was designed to demonstrate non-inferiority.
FDA Priority Review Covers Both MS Populations
Fenebrutinib is an investigational oral, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor designed to cross the blood-brain barrier. Roche is developing the therapy to target B-cell activity associated with acute inflammatory disease activity and microglia within the central nervous system associated with chronic inflammation. Across the three pivotal studies, serious adverse-event rates were generally comparable between treatment groups, although liver enzyme elevations were reported more frequently with fenebrutinib than ocrelizumab in FENtrepid. Roche also reported an imbalance in fatalities across the studies, with deaths occurring at different time points and from different causes. The NDA is now under FDA Priority Review, but fenebrutinib remains investigational in the United States pending regulatory action.
Source :Roche, press release



